Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma

Trial Profile

Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs BAL 101553 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Aug 2017 Status changed from planning to recruiting.
    • 10 Aug 2017 According to a Basilea Pharmaceutica media release, this trial is expected to begin in the fourth quarter of this year.
    • 15 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top